Brookline Capital Management Upgrades BioVie (NASDAQ:BIVI) to Strong-Buy

BioVie (NASDAQ:BIVI) was upgraded by equities researchers at Brookline Capital Management to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

BioVie Stock Up 5.0 %

Shares of BIVI stock opened at $1.06 on Tuesday. The stock has a market cap of $19.56 million, a P/E ratio of -0.11 and a beta of 0.51. The business has a fifty day simple moving average of $1.64 and a 200-day simple moving average of $2.14. BioVie has a fifty-two week low of $0.99 and a fifty-two week high of $7.50.

BioVie (NASDAQ:BIVI) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.46) EPS for the quarter.

Institutional Trading of BioVie

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC acquired a new stake in BioVie in the 4th quarter worth about $28,000. Two Sigma Investments LP acquired a new stake in BioVie in the 4th quarter worth about $57,000. Millennium Management LLC acquired a new stake in BioVie in the 4th quarter worth about $245,000. Northern Trust Corp acquired a new stake in BioVie in the 4th quarter worth about $34,000. Finally, NewEdge Advisors LLC boosted its stake in BioVie by 14,000.0% in the 4th quarter. NewEdge Advisors LLC now owns 14,100 shares of the company’s stock worth $28,000 after buying an additional 14,000 shares during the last quarter. Hedge funds and other institutional investors own 4.59% of the company’s stock.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.